Literature DB >> 11052979

Fibrogenesis. V. TGF-beta signaling pathways.

R G Wells1.   

Abstract

Transforming growth factor (TGF)-beta is a multifunctional peptide growth factor with a wide range of potential effects on growth, differentiation, extracellular matrix deposition, and the immune response. General TGF-beta signaling pathways have been described in detail over the last several years, but factors that determine the nature of the TGF-beta response are poorly understood. In particular, signaling pathways that specifically mediate the matrix effects of TGF-beta have received little attention, although they will be important therapeutic targets in the treatment of pathological fibrosis. This themes article focuses on TGF-beta signaling and highlights potential points for generating matrix-specific responses.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11052979     DOI: 10.1152/ajpgi.2000.279.5.G845

Source DB:  PubMed          Journal:  Am J Physiol Gastrointest Liver Physiol        ISSN: 0193-1857            Impact factor:   4.052


  41 in total

1.  Extraction and purification of TGFbeta and its effect on the induction of apoptosis of hepatocytes.

Authors:  X H Si; L J Yang
Journal:  World J Gastroenterol       Date:  2001-08       Impact factor: 5.742

2.  Losartan reduces trinitrobenzene sulphonic acid-induced colorectal fibrosis in rats.

Authors:  Dov Wengrower; Giuliana Zanninelli; Giovanni Latella; Stefano Necozione; Issa Metanes; Eran Israeli; Joseph Lysy; Mark Pines; Orit Papo; Eran Goldin
Journal:  Can J Gastroenterol       Date:  2012-01       Impact factor: 3.522

Review 3.  Wound healing and fibrosis in intestinal disease.

Authors:  F Rieder; J Brenmoehl; S Leeb; J Schölmerich; G Rogler
Journal:  Gut       Date:  2007-01       Impact factor: 23.059

4.  Iron-loaded cardiac myocytes stimulate cardiac myofibroblast DNA synthesis.

Authors:  Ying Liu; Douglas M Templeton
Journal:  Mol Cell Biochem       Date:  2006-01       Impact factor: 3.396

Review 5.  Gene modulation for treating liver fibrosis.

Authors:  Kun Cheng; Ram I Mahato
Journal:  Crit Rev Ther Drug Carrier Syst       Date:  2007       Impact factor: 4.889

6.  Smad3 specific inhibitor, naringenin, decreases the expression of extracellular matrix induced by TGF-beta1 in cultured rat hepatic stellate cells.

Authors:  Xingjun Liu; Wei Wang; Han Hu; Ning Tang; Chunling Zhang; Wei Liang; Minwei Wang
Journal:  Pharm Res       Date:  2006-12-14       Impact factor: 4.200

Review 7.  Bioconjugation of oligonucleotides for treating liver fibrosis.

Authors:  Zhaoyang Ye; Houssam S Hajj Houssein; Ram I Mahato
Journal:  Oligonucleotides       Date:  2007

8.  Smad3 knock-out mice as a useful model to study intestinal fibrogenesis.

Authors:  Giuliana Zanninelli; Antonella Vetuschi; Roberta Sferra; Angela D'Angelo; Amato Fratticci; Maria Adelaide Continenza; Maria Chiaramonte; Eugenio Gaudio; Renzo Caprilli; Giovanni Latella
Journal:  World J Gastroenterol       Date:  2006-02-28       Impact factor: 5.742

9.  Broad-spectrum matrix metalloproteinase inhibition curbs inflammation and liver injury but aggravates experimental liver fibrosis in mice.

Authors:  Vincent E de Meijer; Deanna Y Sverdlov; Yury Popov; Hau D Le; Jonathan A Meisel; Vânia Nosé; Detlef Schuppan; Mark Puder
Journal:  PLoS One       Date:  2010-06-25       Impact factor: 3.240

10.  Effect of sea buckthorn on liver fibrosis: a clinical study.

Authors:  Ze-Li Gao; Xiao-Hong Gu; Feng-Tao Cheng; Fo-Hu Jiang
Journal:  World J Gastroenterol       Date:  2003-07       Impact factor: 5.742

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.